Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ROBERT EDWARDS�
80.27
+0.35 (0.44%)
After Hours: 77.00 -3.27 (-4.07%)
Apr 24, 6:57PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 78.52 - 80.45
52 week 60.62 - 84.40
Open 80.40
Vol / Avg. 953,166.00/1.49M
Mkt cap 8.61B
P/E 23.42
Div/yield     -
EPS 3.43
Shares 107.24M
Beta 0.47
Inst. own 95%
Jul 21, 2014
Q2 2014 Edwards Lifesciences Earnings Release (Estimated) Add to calendar
May 8, 2014
Edwards Lifesciences Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
Apr 24, 2014
Q1 2014 Edwards Lifesciences Earnings Conference Call - Webcast
Apr 24, 2014
Q1 2014 Edwards Lifesciences Earnings Release
Feb 3, 2014
Q4 2013 Edwards Lifesciences Earnings Conference Call
Feb 3, 2014
Q4 2013 Edwards Lifesciences Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 14.14% 19.15%
Operating margin 18.94% 25.19%
EBITD margin - 25.61%
Return on average assets 11.57% 15.84%
Return on average equity 20.29% 25.78%
Employees 8,600 -
CDP Score - -

Address

One Edwards Way
IRVINE, CA 92614
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Aimee S. Weisner Corporate Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Christine Z. McCauley Corporate Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 51
Bio & Compensation  - Reuters
Bruce P. Garren Corporate Vice President - Public Affairs and Special Counsel
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Kehl Jr. Corporate Vice President - Strategy and Corporate Development
Age: 59
Bio & Compensation  - Reuters
Paul C. Redmond Corporate Vice President - Global Corporate Operations
Age: 49
Bio & Compensation  - Reuters
Carlyn D. Solomon Corporate Vice President - Critical Care and Vascular
Age: 50
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance